BugBiome wins a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures
BioMavericks awarded the wildcard prize as voted for by the audience at the GIANT Health Healthcare Investment Show on 5th December
Sandwich, UK, 6th December 2023 / Sciad Newswire / Discovery Park / BugBiome was announced as the winner of the Discovery Spark life science business support programme at the GIANT Health Healthcare Investment Show on 5th December. BugBiome will be awarded a business support package worth over £…
ValiRx Plc, a life science company focusing on cancer therapeutics and women's health, has announced that ValiRx subsidiary, ValiSeek Ltd, has entered into an exclusive option agreement to license VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.
Ambrose Healthcare is seeking to develop new treatments for rare diseases and patients managed in hospitals and specialist care. The company, incorporated in 2022, has an internationally experienced leadership team with deep knowledge of the pharmaceutical industry.
VAL401 is the reformulation of the established…
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing
PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822
Submission represents first example of an OOC provider’s data supporting clinical progression of a drug for metabolic, fibrotic liver disease
Cambridge, UK, 4 December 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced its PhysioMimix…
Sandwich, Kent, UK, 4th December 2023 / Sciad Newswire / Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1m to £3m, in order to capitalise on exciting investment opportunities and support its existing portfolio. The fund’s investors have committed an additional £2m, which will also enable the fund to take larger stakes in companies that strongly align with its strategic objectives.
DPV was formed in 2022 by Discovery Park to invest in promising, fast-growing life-science companies with close links to the innovation ecosystem at Discovery Park…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR SIGNS CO-DEVELOPMENT AND EXCLUSIVE LICENCE OPTION AGREEMENT WITH LEADING GLOBAL MEDICAL PRODUCTS COMPANY FOR IN-HOUSE SPECIALITY HOSPITAL PRODUCT
Arecor-developed, Arestat™-enabled product is potentially first ready-to-dilute liquid formulation of a high-value oncology therapy
Cambridge, UK, 4 December 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces a co-development and exclusive licence option agreement with a leading global medical products…
Seasoned Life Sciences pharmaceutical physician and leader joins the region’s Life Science & Healthcare membership organisation
One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Judit Molnar, a seasoned pharmaceutical physician and leader, with experience across large pharma and biotech. as a Non-Executive Director. Judit is VP and Head of Early Development, tranScrip, leading the Early Development Team, supporting clients with early development activities from pre-clinical stage…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR CONTINUES COLLABORATION WITH LILLY
Development of an enhanced formulation of Lilly proprietary product using Arecor’s formulation technology platform Arestat™
Cambridge, UK, 29 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with Eli Lilly and Company (“Lilly”).
Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a…
Leading life sciences products and services provider - AMSBIO announce the launch of a custom service providing access to a suite of powerful spatial biology multi-omics profiling tools.
NanoString GeoMx DSP is a new flexible multi-omics platform that enables reliable quantitative assessment of the spatial heterogeneity within various sample types including FFPE, TMAs, and fresh-frozen tissue - with no prequalification required. Tackling the challenge of compromised sample data due to non-target tissue cells, NanoString GeoMx DSP integrates cutting-edge in situ visualization with molecular…
November 2023
Kadans Science Partner given green light for new purpose-built laboratory scheme in King’s Cross, London
London, November 29, 2023 - Kadans Science Partner (“Kadans”) has secured planning permission from the London Borough of Islington, for a new, purpose-built laboratory and office building in London’s Knowledge Quarter, King’s Cross. The new build development has been designed with a specialist professional team and the Kadans Science Partner inhouse development team. This investment represents the physical implementation of Kadans’ long-term model to bolster both specialist…
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesis
Refined focus on neurodegenerative disease targets
Proceeds to be used to advance lead programme targeting FAN1 nuclease in Huntington’s Disease towards the clinic
Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology…